Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets


ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

VIP in Neurological Diseases: More Than A Neuropeptide

Author(s): Maria Morell, Luciana Souza-Moreira and Elena Gonzalez-Rey

Volume 12, Issue 4, 2012

Page: [323 - 332] Pages: 10

DOI: 10.2174/187153012803832549

Price: $65


A hallmark in most neurological disorders is a massive neuronal cell death, in which uncontrolled immune response is usually involved, leading to neurodegeneration. The vasoactive intestinal peptide (VIP) is a pleiotropic peptide that combines neuroprotective and immunomodulatory actions. Alterations on VIP/VIP receptors in patients with neurodenegerative diseases, together with its involvement in the development of embryonic nervous tissue, and findings found in VIP-deficient mutant mice, have showed the relevance of this endogenous peptide in normal physiology and in pathologic states of the central nervous system (CNS). In this review, we will summarize the role of VIP in normal CNS and in neurological disorders. The studies carried out with this peptide have demonstrated its therapeutic effect and render it as an attractive candidate to be considered in several neurological disorders linked to neuroinflammation or abnormal neural development.

Keywords: Neuroimmunology, neuroinflammatory diseases, neurological disorders, neuropeptides, VIP, TISSUE EXPRESSION, NORMAL ADULT BRAIN PHYSIOLOGY, neuroendocrine–immune communication, Neuroimmune interactions, multiple sclerosis (MS), Parkinson’s and Alzheimer´s disease (PD) and AD, NEURODEVELOPMENTAL DISORDERS.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy